<DOC>
	<DOCNO>NCT01775774</DOCNO>
	<brief_summary>This Phase 1 , open label , dose escalation , multi-center clinical trial Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells ( hMSCs ) treatment Acute Respiratory Distress Syndrome ( ARDS ) . The purpose study assess safety hMSCs patient ARDS .</brief_summary>
	<brief_title>Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome</brief_title>
	<detailed_description>The primary objective study assess safety intravenous infusion Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells ( hMSCs ) patient ARDS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<criteria>Patients eligible inclusion meet criterion . Criteria 13 must present within 24hour time period time enrollment : Acute onset ( define ) : 1 . A need positive pressure ventilation endotracheal tracheal tube PaO2/FiO2 ratio &lt; 200 least 8 cm H2O positive endexpiratory airway pressure ( PEEP ) 2 . Bilateral infiltrates consistent pulmonary edema frontal chest radiograph 3 . No clinical evidence leave atrial hypertension bilateral pulmonary infiltrates . In addition meeting inclusion criterion , enrollment must occur within 96hours first meeting ARDS criterion per Berlin definition ARDS . 1 . Age le 18 year 2 . Greater 96 hour since first meeting ARDS criterion per Berlin definition ARDS 3 . Pregnant breastfeed 4 . Prisoner 5 . Presence active malignancy ( nonmelanoma skin cancer ) require treatment within last 2 year 6 . Any irreversible disease condition 6month mortality estimate great 50 % 7 . Moderate severe liver failure ( ChildsPugh Score &gt; 12 ) 8 . Severe chronic respiratory disease PaCO2 &gt; 50 mm Hg use home oxygen 9 . Patient , surrogate , physician commit full support ( exception : patient exclude he/she would receive supportive care except attempt resuscitation cardiac arrest ) . 10 . Major trauma prior 5 day 11 . Lung transplant patient 12 . No consent/inability obtain consent 13 . Moribund patient expect survive 24 hour 14. WHO Class III IV pulmonary hypertension 15 . Documented deep venous thrombosis pulmonary embolism within past 3 month 16 . No arterial line/no intent place arterial line 17 . No intent/unwillingness follow lung protective ventilation strategy fluid management protocol 18 . Currently receive extracorporeal life support ( ECLS ) highfrequency oscillatory ventilation ( HFOV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Acute Respiratory Distress Syndrome</keyword>
	<keyword>Acute Lung Injury</keyword>
	<keyword>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells</keyword>
</DOC>